STOCKWATCH
·
Pharmaceuticals
Quarterly Result27 May 2025, 05:32 am

Kerala Ayurveda Ltd Reports 22% FY 25 Revenue Growth, Aims for 50% in FY 26

AI Summary

Kerala Ayurveda Ltd (KAL) reported a 22% growth in consolidated FY’25 revenue to Rs. 137.2 Crs. Despite investments in marketing, talent hiring, and technology, the company managed to keep Adjusted* EBITDA positive at Rs. 3.1 Crs. KAL plans to double its growth rate in the year ahead to 50% topline growth with continued investments in chosen drivers of growth - the digital and health service businesses powered by world class talent, marketing, technology, and international expansion. The company's India Ecommerce business saw a continued upswing in growth with Q4’25 growing at 37% vs. year ago.

Key Highlights

  • Consolidated FY’25 revenue grew by 22%
  • Adjusted* EBITDA positive at Rs. 3.1 Crs.
  • Plans to double growth rate to 50% in the new financial year
  • Significant investments in high quality marketing, advanced technology, and expanded international reach
  • India Ecommerce business grew 37% in Q4’25
KERALAYUR
Pharmaceuticals
KERALA AYURVEDA LTD.

Price Impact